"Calithera has made significant accomplishments, both financially and operationally, through the third quarter of this year," said
Selected Third Quarter 2014 Financial Results
Cash and cash equivalents totaled
Research and development expenses for the three months ended
General and administrative expenses for the three months ended
About Calithera
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Such statements contained in this press release include expectations regarding the timing of initiation and enrollment of our clinical trials. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in forward-looking statements, as well as risks relating to Calithera's business in general, see Calithera's prospectus dated
Calithera Biosciences, Inc. | ||||
Selected Statements of Operations Financial Data | ||||
(in thousands) | ||||
(unaudited) | ||||
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||
2014 | 2013 | 2014 | 2013 | |
Operating expenses: | ||||
Research and development | $ 3,894 | $ 2,735 | $ 11,395 | $ 6,804 |
General and administrative | 1,347 | 583 | 3,488 | 1,486 |
Total operating expenses | 5,241 | 3,318 | 14,883 | 8,290 |
Loss from operations | (5,241) | (3,318) | (14,883) | (8,290) |
Other income | 2 | — | 4 | — |
Net loss and comprehensive loss | $ (5,239) | $ (3,318) | $ (14,879) | $ (8,290) |
Calithera Biosciences, Inc. | ||
Selected Balance Sheets Financial Data | ||
(in thousands) | ||
(unaudited) | ||
September 30, 2014 |
December 31, 2013 |
|
Balance Sheet Data: | ||
Cash and cash equivalents | $ 34,852 | $ 33,820 |
Working capital | 32,128 | 32,825 |
Total assets | 39,642 | 34,844 |
Accumulated deficit | (45,021) | (30,142) |
Total stockholders' (deficit) equity | (35,013) | (20,813) |
CONTACT:Jennifer McNealey ir@Calithera.com 650-870-1071